表紙
市場調査レポート

前立腺癌治療市場:2016年〜2026年

The Prostate Cancer Market 2016-2026: Increasing Incidence and Promising New Therapies to Drive Market Growth

発行 Visiongain Ltd 商品コード 282256
出版日 ページ情報 英文 228 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.02円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
前立腺癌治療市場:2016年〜2026年 The Prostate Cancer Market 2016-2026: Increasing Incidence and Promising New Therapies to Drive Market Growth
出版日: 2016年04月28日 ページ情報: 英文 228 Pages
概要

当レポートでは、世界の前立腺癌治療市場について調査分析し、市場概要、セグメント別の収益予測、主要企業プロファイル、主要国市場、定性分析など、体系的な情報を提供しています。

第1章 レポート概要

第2章 前立腺癌のイントロダクション

  • 癌とは
  • 癌細胞の表現型の特徴
  • 癌の原因
    • 世界の癌患者数:世界の状況
  • 前立腺癌とは
    • 世界の前立腺癌患者数:世界的な急増
    • 前立腺癌の危険因子
  • 前立腺癌の診断方法
  • 前立腺癌の治療

第3章 前立腺癌治療市場

  • 世界の前立腺癌治療市場
  • 世界の前立腺癌治療市場の予測
  • 世界の前立腺癌治療市場:促進要因と抑制要因

第4章 前立腺癌治療薬市場

  • 前立腺癌治療薬市場:選択薬の増加によって競争が激化
  • 前立腺癌治療薬市場
  • 主要な前立腺癌治療薬:市場予測
  • 第1世代の化学療法
    • Taxotere (Sanofi)
  • 第2世代の化学療法
    • Jevtana (Sanofi)
  • 第1世代のホルモン
    • Casodex (AstraZeneca)
    • Leupoin (武田薬品工業)/Lupron (AbbVie)
    • Zoladex (AstraZeneca)
  • 第2世代のホルモン
    • Zytiga (Johnson & Johnson)
    • Xtandi (Medivation/アステラス製薬)
  • 放射性医薬品
    • Xofigo (Bayer)
  • その他の治療薬
  • 前立腺癌治療薬のパイプライン
    • 第3相
    • 第2相
    • 第1相

第5章 前立腺癌装置市場

  • 前立腺癌装置市場
  • 前立腺癌装置市場の予測
  • 主要な前立腺癌装置市場の市場シェア
  • 前立腺全摘出術市場
  • 外照射療法 (EBRT) 市場
  • 小線源療法市場
  • 凍結療法市場
  • HIFU市場

第6章 前立腺癌治療市場の主要企業

  • 前立腺癌治療薬市場の主要企業
  • Johnson & Johnson (J&J)
  • AstraZeneca
  • Sanofi
  • AbbVie
  • 前立腺癌装置市場の主要企業
  • Varian Medical Systems
  • Elekta
  • Theragenics Corporation

第7章 主要国市場

  • 前立腺癌治療市場の地域別分析
  • 前立腺癌治療市場の地域別予測
  • 前立腺癌治療市場の主要国の市場シェア予測
  • 米国
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • イタリア
  • 日本
  • 中国
  • ブラジル
  • ロシア
  • インド
  • 韓国
  • その他

第8章 前立腺癌治療市場の定性分析

  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • ファイブフォース分析

第9章 結論

  • 前立腺癌治療市場
  • 米国:2016年〜2026年も最大国市場
  • 結論

第10章 用語集

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0113

What can be expected from the prostate cancer market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 228-page report provides 213 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole prostate cancer therapeutics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

The report also includes revenue forecasts to 2026 for the following submarkets in the prostate cancer market:

  • Prostate Cancer Drugs - including revenue forecasts to 2026 for:
  • Zytiga
  • Xtandi
  • Leuplin
  • Lupron
  • Jevtana
  • Zoladex
  • Casodex
  • Xofigo
  • Taxotere
  • Prostate Cancer Devices - including revenue forecasts to 2026 for:
  • Radical Prostatectomy
  • External Beam Radiation Therapy
  • Brachytherapy
  • High-Intensity Focused Ultrasound (HIFU)
  • Cryotherapy

The report also includes revenue forecasts to 2026 for the following national and regional markets for prostate cancer:

  • US
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Japan
  • China
  • India
  • Russia
  • Brazil
  • South Korea

The report provides detailed profiles of key companies operating within the prostate cancer market:

  • Johnson & Johnson
  • AstraZeneca
  • Sanofi
  • AbbVie
  • Varian Medical Systems
  • Elekta
  • Theragenics

Leading companies and potential for market growth

Overall revenue for the prostate cancer market will reach $12.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in prostate cancer devices, treatments with more favourable side effect profiles and the launch of several new therapies in both early and late stage prostate cancer will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of 7 leading companies, including these:

  • Johnson & Johnson
  • AstraZeneca
  • Sanofi
  • AbbVie
  • Varian Medical Systems
  • Elekta
  • Theragenics

image1

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Historic revenue, analysis and discussion of company performance over the past 5 years (where available)
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the prostate cancer therapeutics industry?

Our new report discusses issues and events affecting the prostate cancer therapeutics market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of key therapeutic indications
  • Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Prostate Cancer Market 2016-2026 report helps you

In summary, our 228-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the Prostate Cancer market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for each major submarket - discover prospects for leading prostate cancer products in the following areas: prostate cancer drugs and prostate cancer devices.
  • Revenue forecasts to 2026 for 9 leading drugs - discover prospects for leading prostate cancer drugs including: Zytiga, Xtandi, Leuplin, Lupron, Jevtana, Zoladex, Casodex, Xofigo and Taxotere
  • Revenue forecasts to 2026 for 5 leading device markets - discover prospects for leading prostate cancer device including: Radical Prostatectomy, External Beam Radiation Therapy, Brachytherapy, High-Intensity Focused Ultrasound (HIFU) and Cryotherapy devices
  • Revenue forecasts to 2026 for twelve leading national markets - US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea
  • Assessment of 7 leading companies - analysis of products, revenue, mergers & acquisitions, sales by region and products
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the prostate cancer market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1. The Prostate Cancer Therapeutics Market Overview
  • 1.2. Prostate Cancer Therapeutics Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. Introduction to Prostate Cancer

  • 2.1. What Is Cancer?
  • 2.2. Phenotypic Characteristics of Cancer Cells
  • 2.2.1. Uncontrolled Growth
  • 2.2.2. Loss of Functioning Apoptotic Pathways
  • 2.2.3. Lack of Differentiation
  • 2.2.4. Increased Angiogenesis
  • 2.2.5. Potential for Metastasis
  • 2.2.6. Genetic Instability
  • 2.3. What Causes Cancer?
  • 2.3.1. Worldwide Prevalence of Cancer: A Global Picture
  • 2.4. What is Prostate Cancer?
  • 2.4.1. Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
  • 2.4.2. Risk Factors for Prostate Cancer
  • 2.5. How is Prostate Cancer Diagnosed?
  • 2.5.1. PSA Testing
  • 2.5.2. Digital Rectal Examination Testing
  • 2.5.3. Prostate Cancer Screening: Does the Cost Justify the Means?
  • 2.5.4. Alternative Tests Could Change Diagnostics
  • 2.6. Treating Prostate Cancer
  • 2.6.1. Localised Prostate Cancer: Surgery/Radiation is Most Preferred
    • 2.6.1.1. Brachytherapy
    • 2.6.1.2. Radical Prostatectomy
    • 2.6.1.3. External Beam Radiation Therapy
    • 2.6.1.4. Cryotherapy
    • 2.6.1.5. High-Intensity Focused Ultrasound (HIFU)
  • 2.6.2. Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
  • 2.6.3. Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
  • 2.6.4. Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
  • 2.6.5. First Line Chemotherapy: Docetaxel is a Standard Treatment
  • 2.6.6. Post Docetaxel Therapy: Five FDA Approved Drugs
  • 2.6.7. Second Line Chemotherapy: Jevtana Approved in 2010

3. The Prostate Cancer Therapeutics Market 2016-2026

  • 3.1. The Global Prostate Cancer Therapeutics Market, 2014
  • 3.2. The Global Prostate Cancer Therapeutics Market Forecast, 2016-2026
  • 3.3. The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2016-2026

4. The Prostate Cancer Drugs Market 2016-2026

  • 4.1. The Prostate Cancer Drugs Market: Greater Choice of Drugs Increasing Competition in the mCRPC Setting
  • 4.2. The Prostate Cancer Drugs Market, 2015
  • 4.3. Leading Prostate Cancer Drugs: Market Forecast, 2015-2025
  • 4.4. Market Share of Leading Prostate Cancer Drugs, 2016-2026
  • 4.5. First Generation Chemotherapies
  • 4.5.1. Taxotere (Sanofi)s
    • 4.5.1.1. Taxotere Sales, 2014
    • 4.5.1.2. Taxotere Sales Forecast, 2016-2026
  • 4.6. Second Generation Chemotherapies
  • 4.6.1. Jevtana (Sanofi)
    • 4.6.1.1. Jevtana Sales, 2014 & 2015
    • 4.6.1.2. Jevtana Sales Forecast, 2016-2026
  • 4.7. First Generation Hormones
  • 4.7.1. Casodex (AstraZeneca)
    • 4.7.1.1. Casodex Sales, 2014 & 2015
    • 4.7.1.2. Casodex Sales Forecast, 2016-2026
  • 4.7.2. Leuplin (Takeda) / Lupron (AbbVie)
    • 4.7.2.1. Leuplin & Lupron Sales, 2014 & 2015
    • 4.7.2.2. Leuplin & Lupron Sales Forecast, 2016-2026
  • 4.7.3. Zoladex (AstraZeneca)
    • 4.7.3.1. Zoladex Sales, 2014 & 2015
    • 4.7.3.2. 2 Zoladex Sales Forecast, 2015-2025
  • 4.8. Second Generation Hormones
  • 4.8.1. Zytiga (Johnson & Johnson)
    • 4.8.1.1. Zytiga Sales, 2014 & 2015
    • 4.8.1.2. Zytiga Sales Forecast, 2016-2026
  • 4.8.2. Xtandi (Medivation/ Astellas Pharma)
    • 4.8.2.1. Xtandi Sales, 2014 & 2015
    • 4.8.2.2. Xtandi Sales Forecast, 2016-2026
  • 4.9. Radiopharmaceuticals
  • 4.9.1. Xofigo (Bayer)
    • 4.9.1.1. Xofigo Sales, 2014 & 2015
    • 4.9.1.2. Xofigo Sales Forecast, 2016-2026
  • 4.10. Other Drugs
  • 4.11. Prostate Cancer Drugs Pipeline, 2016
    • 4.11.1. Phase III Development
      • 4.11.1.1. DCVax-Prostate (NorthWest Biotherapeutics)
      • 4.11.1.2. Tookad Soluble (Steba Biotech)
      • 4.11.1.3. ProstAtak (Advantagene)
      • 4.11.1.4. ARN-509 (Johnson & Johnson)
      • 4.11.1.5. Custirsen (Oncogenex)
      • 4.11.1.6. Prostvac (Bavarian Nordic)
      • 4.11.1.7. Galeterone (Tokai Pharmaceuticals)
    • 4.11.2. Phase II development
      • 4.11.2.1. GDC-0068 (Roche)
      • 4.11.2.2. PSMA ADC (Progenics Pharmaceuticals)
      • 4.11.2.3. Apatorsen (OGX-427 - OncoGenex Pharmaceuticals)
    • 4.11.3. Phase I
      • 4.11.3.1. RG7450 (Roche)
      • 4.11.3.2. BAY2010112 (Bayer Pharmaceuticals)
      • 4.11.3.3. BPX-201 (Bellicum Pharmaceuticals)

5. The Prostate Cancer Devices Market, 2016-2026

  • 5.1. The Prostate Cancer Devices Market 2014
  • 5.2. The Prostate Cancer Devices Market Forecast, 2016-2026
  • 5.3. The Market Shares of Leading Prostate Cancer Devices Submarkets, 2016-2026
  • 5.4. The Radical Prostatectomy Market 2016-2026
  • 5.4.1. Intuitive Surgical's da Vinci Surgical System
  • 5.5. The External Beam Radiation Therapy Market, 2016-2026
  • 5.6. The Brachytherapy Market 2016-2026
  • 5.7. The Cryotherapy Market 2016-2026
  • 5.8. The HIFU Market, 2016-2026

6. The Leading Companies in the Prostate Cancer Therapies Market, 2016

  • 6.1. The Leading Companies in the Prostate Cancer Drugs Market, 2016
  • 6.2. Johnson & Johnson (J&J)
  • 6.2.1. Sales and Performance Analysis, 2015
  • 6.2.2. Pharmaceutical Segment Sales Analysis, 2015
  • 6.2.3. Oncology Drugs Sales and Performance Analysis, 2015
  • 6.2.4. Pharmaceutical Segment R&D Performance Analysis, 2015
  • 6.2.5. Acquisition of Aragon Pharmaceuticals
  • 6.3. AstraZeneca
  • 6.3.1. Sales and Performance Analysis, 2015
  • 6.3.2. Pharmaceutical Segment Sales & R&D Analysis by Segment, 2015
  • 6.3.3. Oncology Drugs Sales and Performance Analysis, 2015
  • 6.4. Sanofi
  • 6.4.1. Sales and Performance Analysis, 2015
  • 6.4.2. Sales and Performance Analysis by Segment, 2015
  • 6.4.3. Oncology Sales and Performance Analysis, 2015
  • 6.4.4. R&D Performance Analysis, 2015
  • 6.4.5. Oncology Pipeline Portfolio
  • 6.5. AbbVie
  • 6.5.1. Sales and Performance Analysis, 2015
  • 6.5.2. R&D Performance Analysis, 2015
  • 6.5.3. Humira: From "First-In-Class" to "Best-In-Class", 2015
  • 6.5.4. Oncology Portfolio Pipeline Products, 2015
  • 6.6. Leading Companies in the Prostate Cancer Devices Market 2016-2026
  • 6.7. Varian Medical Systems
  • 6.7.1. Sales and Performance Analysis, 2015
  • 6.7.2. Oncology Segment Sales Analysis, 2015
  • 6.7.3. Sales Analysis by Region, 2015
  • 6.7.4. R&D Performance Analysis, 2015
  • 6.7.5. Key Oncology Products, 2015
  • 6.7.6. Varian and Siemens Partnership: Shaping the Future of Cancer Care
  • 6.8. Elekta
  • 6.8.1. Sales and Performance Analysis, 2015
  • 6.8.2. Sales and Performance Analysis by Region, 2015
  • 6.8.3. Elekta and Philips Establish Research Consortium
  • 6.8.4. Product Launch and Development, 2015
  • 6.9. Theragenics Corporation (acquired by Juniper Acquisition Corporation)
  • 6.9.1. Theragenics Sales Performance Analysis, 2014
  • 6.9.2. Theragenics Sales Performance by Operation, 2012
  • 6.9.3. Sales and Performance Analysis by Business Unit, 2012
  • 6.9.4. Mergers and Acquisitions
  • 6.9.4.1. Juniper's acquisition of Theragenics
  • 6.9.4.2. Acquisition of US & Canadian Seed Business of Eckert & Ziegler BEBIG
  • 6.9.4.3. Acquisition of Needle Tech Products
  • 6.9.4.4. Acquisition of Galt Medical

7. The Leading National Markets, 2016-2026

  • 7.1. Regional Breakdown of the Prostate Cancer Therapeutics Market, 2014
  • 7.2. The Prostate Cancer Therapeutics Market: Regional Forecast, 2016-2026
  • 7.3. Market Shares Forecasts of Leading National Prostate Cancer Therapeutics Markets, 2016-2026
  • 7.4. The US Prostate Cancer Therapeutics Market 2016-2026
  • 7.5. The European Prostate Cancer Therapeutics Market, 2014
  • 7.6. The European Prostate Cancer Therapeutics Market, 2015-2025
  • 7.6.1. The German Prostate Cancer Therapeutics Market, 2016-2026
  • 7.6.2. The French Prostate Cancer Therapeutics Market, 2016-2026
  • 7.6.3. The UK Prostate Cancer Therapeutics Market, 2015-2025
  • 7.6.4. The Spanish Prostate Cancer Therapeutics Market, 2016-2026
  • 7.6.5. The Italian Prostate Cancer Therapeutics Market, 2016-2026
  • 7.7. The Japanese Prostate Cancer Therapeutics Market, 2016-2026
  • 7.8. The Chinese Prostate Cancer Therapeutics Market, 2016-2026
  • 7.9. The Brazilian Prostate Cancer Therapeutics Market, 2016-2026
  • 7.10. The Russian Prostate Cancer Therapeutics Market, 2016-2026
  • 7.11. The Indian Prostate Cancer Therapeutics Market, 2016-2026
  • 7.12. The South Korean Prostate Cancer Therapeutics Market, 2016-2026
  • 7.13. The Rest of the World Prostate Cancer Therapeutics Market, 2016-2026

8. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2016-2026

  • 8.1. SWOT Analysis, 2016-2026
  • 8.2. Strengths
  • 8.2.1. Rapidly Ageing Male Populations Worldwide
  • 8.2.2. A Number of Promising Pipeline Drug Candidates
  • 8.2.3. Successful Partnerships Between Big and Small Pharmaceutical Companies Leading to New Products
  • 8.3. Weaknesses
  • 8.3.1. High Treatment Costs
  • 8.3.2. High Levels of Phase III Attrition
  • 8.4. Opportunities
  • 8.4.1. Rising Incidence of Cancer
  • 8.4.2. Development of Emerging Markets
  • 8.5. Threats
  • 8.5.1. Concerns about Efficacy and Toxicity of Drugs
  • 8.5.2. Increase in Generic Competition
  • 8.5.3. Healthcare Budget Restraints
  • 8.6. Porter's Five Force Analysis
  • 8.6.1. Rivalry Among Competitors [High]
  • 8.6.2. Threat of New Entrants [High]
  • 8.6.3. Power of Suppliers [Low]
  • 8.6.4. Power of Buyers [High]
  • 8.6.5. Threat of Substitutes [Low]

9. Conclusions

  • 9.1. The Prostate Cancer Therapeutics Market, 2016-2026
  • 9.2. The US Will Remain the Largest National Market from 2016 to 2026
  • 9.3. Concluding Remarks

10. Glossary

Appendix

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1 Global Prostate Cancer Therapies Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2014-2020 (Altered Data)
  • Table 2.1 PSA Testing: Benefits and Limitations, 2016
  • Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2015
  • Table 2.3 Advantages and Disadvantages of Brachytherapy, 2016
  • Table 2.4 Advantages and Disadvantages of Radical Prostatectomy, 2016
  • Table 2.5 Advantages and Disadvantages of External Beam Radiation, 2016
  • Table 2.6 Advantages and Disadvantages of Cryotherapy, 2016
  • Table 2.7 Advantages and Disadvantages of HIFU, 2016
  • Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Segment, 2014
  • Table 3.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2016-2026
  • Table 4.1 The Prostate Cancer Drugs List: Key Brands, 2015
  • Table 4.2 The Prostate Cancer Drugs Market: Revenue ($m), Market Share (%) by Leading Drugs, 2015
  • Table 4.3 The Prostate Cancer Drugs Market Forecast by Leading Drugs, Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.4 The Prostate Cancer Drugs Market Forecast by Leading Drugs, Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.5 Market Shares (%) of the Leading Prostate Cancer Drugs, 2020 and 2026
  • Table 4.6 Sanofi: Taxotere Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.7 Sanofi: Taxotere Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.8 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.9 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.10 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.11 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.12 Takeda: Leuplin Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 4.13 Takeda: Leuplin Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.14 AbbVie: Lupron Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.15 AbbVie: Lupron Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.16 Zoladex (AstraZeneca): Zoladex Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.17 Zoladex (AstraZeneca): Zoladex Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.18 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.19 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.20 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.21 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.22 Bayer: Xofigo Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.23 Bayer: Xofigo Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.24 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.25 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 4.26 Key Drugs in Phase III Clinical Trials , 2016
  • Table 4.27 Key Drugs in Phase II Clinical Trials , 2016
  • Table 4.28 Key Drugs in Phase I Clinical Trials, 2016
  • Table 5.1 The Prostate Cancer Devices Market: Revenue ($m) and Market Share (%) by Segment, 2014
  • Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Segment, 2014-2020
  • Table 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Segment, 2020-2026
  • Table 5.4 The Prostate Cancer Devices Market Forecast: Revenue ($m) and Market Shares (%), 2014, 2020 and 2026
  • Table 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.6 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 5.7 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.8 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.9 The Brachytherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.10 The Brachytherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 5.11 The Cryotherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.12 The Cryotherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 5.13 The HIFU Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.14 The HIFU Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 6.1 Johnson & Johnson: Revenue ($m) and Revenue Share (%) by Segment, 2015
  • Table 6.2 Johnson & Johnson: Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
  • Table 6.3 Johnson & Johnson Pharmaceuticals: Revenue ($bn), and Revenue Shares (%) by Segment, 2015
  • Table 6.4 Johnson & Johnson Pharmaceuticals: Top 5 Best Selling Drugs, Revenue ($bn) and Revenue Share (%) 2015
  • Table 6.5 Johnson & Johnson: Oncology Pharmaceuticals Segment: Revenue ($m) and Percentage Share (%) by Drug, 2014-2015
  • Table 6.6 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2010-2015
  • Table 6.7 AstraZeneca: Revenue ($bn), AGR (%), 2010-2015
  • Table 6.8 AstraZeneca: Revenue ($bn), Revenue Shares (%) by Segment, 2015
  • Table 6.9 AstraZeneca: R&D Expenditure ($bn), Revenue ($bn) and R&D Expenditure as a Percentage of Sales, 2010-2015
  • Table 6.10 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2015
  • Table 6.11 AstraZeneca Oncology: Investigational Oncology Compounds in Mid to Late Stage Clinical Trials, 2015
  • Table 6.12 Sanofi: Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
  • Table 6.13 Sanofi: Global Sales Revenue ($bn), Percentage Change (%) and Percentage Change at Constant Exchange Rates (%) by Region, 2014-2015
  • Table 6.14 Sanofi: Sale Revenue ($bn) and Revenue Shares (%) by Segment, 2015
  • Table 6.15 Sanofi: Revenue ($m) and Revenue Share (%) by Sub-Segments, 2015
  • Table 6.16 Sanofi: Oncology Sales ($m) and Revenue Share (%) by Product, 2015
  • Table 6.17 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2015
  • Table 6.18 Sanofi: Major Compounds from Sanofi's Oncology Pipeline, 2015
  • Table 6.19 AbbVie: Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
  • Table 6.20 AbbVie Main Products: Revenue ($m) 2013-2015
  • Table 6.21 AbbVie: Humira Indications by Regions, 2016
  • Table 6.22 Varian Medical Systems: Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
  • Table 6.23 Varian Medical Systems: Revenue ($bn) and Revenue Share (%), 2015
  • Table 6.24 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Segment, 2015
  • Table 6.25 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Region, 2015
  • Table 6.26 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2015
  • Table 6.27 Elekta: Revenue ($bn), AGR (%) and CAGR (%) 2010-2015
  • Table 6.28 Elekta: Revenue ($m), by Country 2014-2015
  • Table 6.29 Theragenics: Revenue ($m), AGR (%) and CAGR (%) 2008-2012
  • Table 6.30 Theragenics: Revenue ($m) and Revenue Share (%) by Business Unit, 2012
  • Table 7.1 The Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Region, 2014
  • Table 7.2 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.3 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.4 Revenue ($m) and Market Shares (%) of the Leading Prostate Cancer Therapeutics National Markets, 2014, 2020 and 2026
  • Table 7.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.6 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.7 The European Prostate Cancer Therapeutics Markets: Revenue ($m), Market Share (%) by Country/Region, 2014
  • Table 7.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.9 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.10 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.11 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.12 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.13 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.14 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.15 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.16 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.17 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.18 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.19 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.20 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.21 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.22 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.23 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.24 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.25 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.26 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.27 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.28 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.29 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.30 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.31 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.32 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.33 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 8.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2016-2026

List of Figures

  • Figure 1.1 Prostate Cancer Therapeutics: Overview of Submarkets and Segments
  • Figure 2.1 Risk Factors Associated with Cancer Development
  • Figure 2.2 Global Proportion (%) of Newly Diagnosed Cancer by Type (Excluding Non-Melanoma Skin Cancer), 2012
  • Figure 2.3 Risk Factors Associated with Prostate Cancer Development
  • Figure 2.4 Prostate Cancer Incidence and Mortality in the US per 100,000 people, by Ethnicity, 2007-2011
  • Figure 2.5 Treatment Sequence for Prostate Cancer, 2016
  • Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) by Segment, 2014
  • Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Share (%) by Segment, 2014
  • Figure 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($m) by Leading Drugs, 2015
  • Figure 4.2 The Prostate Cancer Drugs Market: Market Share (%) by Leading Drugs, 2015
  • Figure 4.3 The Prostate Cancer Drugs Market Forecast, Revenue ($m) and AGR (%), 2014-2026
  • Figure 4.4 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2020
  • Figure 4.5 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2026
  • Figure 4.6 Taxotere (Sanofi): Taxotere Revenue Forecast ($m) and AGR (%) 2014-2026
  • Figure 4.7 Sanofi: Jevtana Revenue Forecast ($m) and AGR (%) 2014-2026
  • Figure 4.8 AstraZeneca: Casodex Revenue Forecast ($m) and AGR (%) 2014-2026
  • Figure 4.9 Takeda: Leuplin Prostate Cancer Revenue Forecast ($m) and AGR (%) 2014-2026
  • Figure 4.10 AbbVie: Lupron Prostate Cancer Revenue Forecast ($m) and AGR (%) 2014-2026
  • Figure 4.11 AstraZeneca: Zoladex Prostate Cancer Revenue Forecast ($m) and AGR (%) 2014-2026
  • Figure 4.12 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%),2014-2026
  • Figure 4.13 Medivation/Astellas: Xtandi Revenue Forecast ($m) and AGR (%), 2014-2026
  • Figure 4.14 Bayer: Xofigo Revenue Forecast ($m) and AGR (%), 2014-2026
  • Figure 4.15 Other Prostate Cancer Drugs: Revenue Forecast ($m) and AGR (%), 2014-2026
  • Figure 5.1 Segmentation of the Prostate Cancer Devices Market, 2016
  • Figure 5.2 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2014
  • Figure 5.3 The Prostate Cancer Devices Market: Market Share (%) by Segment, 2014
  • Figure 5.4 The Prostate Cancer Devices Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 5.5 The Prostate Cancer Devices Market Segments: Revenue ($m) Forecast, 2014, 2020, 2026
  • Figure 5.6 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2020
  • Figure 5.7 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2026
  • Figure 5.8 The Radical Prostatectomy Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 5.9 The External Beam Radiation Therapy Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 5.10 The Brachytherapy Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 5.11 The Cryotherapy Market Forecast: Revenue ($m), AGR (%), 2014-2026
  • Figure 5.12 The HIFU Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.1 Johnson & Johnson: Revenue Shares (%) by Segment, 2014
  • Figure 6.2 Johnson & Johnson: Historical Revenue ($bn) and AGR (%), 2010-2015
  • Figure 6.3 Johnson & Johnson Pharmaceuticals: Revenue ($bn) by Segment, 2015
  • Figure 6.4 Johnson & Johnson Pharmaceuticals: Revenue Share (%) by Segment, 2015
  • Figure 6.5 Johnson & Johnson Pharmaceuticals: Revenue Shares (%) by Leading Drugs, 2015
  • Figure 6.6 Johnson & Johnson Oncology Pharmaceuticals Segment: Revenue Share (%) by Drug, 2014
  • Figure 6.7 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2011-2015
  • Figure 6.8 AstraZeneca: Revenue ($bn), AGR (%), 2010-2015
  • Figure 6.9 AstraZeneca: Revenue ($bn) by Segment, 2015
  • Figure 6.10 AstraZeneca: Revenue Shares (%) by Segment, 2015
  • Figure 6.11 AstraZeneca Performance: R&D Costs ($bn) and Percentage of Sales (%), 2010-2015
  • Figure 6.12 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2015
  • Figure 6.13 AstraZeneca: Revenue Share (%) of Oncology Drugs, 2015
  • Figure 6.14 Sanofi: Historical Revenue ($bn) and AGR (%), 2010-2015
  • Figure 6.15 Sanofi: Global Sales Revenue ($bn) and Percentage Change (%) by Region, 2014-2015
  • Figure 6.16 Sanofi: Revenue ($bn) by Segment, 2015
  • Figure 6.17 Sanofi: Revenue Share (%) by Segment, 2015
  • Figure 6.18 Sanofi: Pharmaceutical Sub-segment Revenue Share (%), 2015
  • Figure 6.19 Sanofi: Oncology Revenue ($bn) by Product, 2015
  • Figure 6.20 Sanofi: Oncology Revenue Share (%) by Product, 2015
  • Figure 6.21 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Net Sales (%), 2010-2015
  • Figure 6.22 AbbVie: Revenue ($bn) and AGR (%), 2010-2015
  • Figure 6.23 AbbVie Main Products: Revenue ($m) Comparison, 2013-2015
  • Figure 6.24 AbbVie: Revenue Share (%) by Drug, 2015
  • Figure 6.25 Varian Medical Systems: Revenue ($bn) and AGR(%), 2010-2015
  • Figure 6.26 Varian Medical Systems: Revenue ($bn) by Segment, 2015
  • Figure 6.27 Varian Medical Systems: Revenue Share (%) by Segment, 2015
  • Figure 6.28 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2015
  • Figure 6.29 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2015
  • Figure 6.30 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2015
  • Figure 6.31 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2015
  • Figure 6.32 Elekta: Historical Revenue ($bn) and AGR (%), 2010-2015
  • Figure 6.33 Elekta: Historical Revenue ($m), by Country 2014-2015
  • Figure 6.34 Elekta: Revenue Share (%) by Country 2015
  • Figure 6.35 Theragenics: Revenue ($m) and AGR (%), 2008-2012
  • Figure 6.36 Theragenics: Revenue Share (%) by Operation, 2012
  • Figure 6.37 Theragenics: Revenue ($m) by Business Unit, 2012
  • Figure 6.38 Theragenics: Revenue Share (%) by Business Unit, 2012
  • Figure 7.1 The Prostate Cancer Therapeutics Market: Revenue ($m) by Region, 2014
  • Figure 7.2 The Prostate Cancer Therapeutics Market: Market Share (%) by Region, 2014
  • Figure 7.3 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2020
  • Figure 7.4 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2026
  • Figure 7.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.6 The European Prostate Cancer Therapeutics Markets: Revenue ($m) by Country / Region, 2014
  • Figure 7.7 The European Prostate Cancer Therapeutics Markets: Market Share (%) by Country / Region, 2014
  • Figure 7.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 7.9 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.10 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Figure 7.11 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2026
  • Figure 7.12 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2026
  • Figure 7.13 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.14 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.15 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.16 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.17 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.18 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.19 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 7.20 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 8.1 Porter's Five Force Analysis of the Prostate Cancer Therapeutics Market, 2016-2026

Companies Listed

  • AbbVie
  • Accord Healthcare Inc.
  • Actavis
  • Advanced Medical Isotope Corporation
  • Advantagene
  • Algeta ASA
  • Almirall
  • Aragon Pharmaceuticals
  • Astellas Pharmacueticals
  • AstraZeneca
  • Bavarian Nordic
  • Bayer Healthcare
  • Bayer Pharmaceuticals
  • Beckman Coulter
  • Bellicum Pharmaceuticals
  • Bostwick Laboratiories
  • Breckenridge Pharmaceuticals
  • Bristol Myers Squibb (BMS)
  • BTG Plc
  • Computer Motion
  • Cougar Biotechnology
  • CR Bard
  • Danaher Corporation
  • Dendreon
  • Eckert & Ziegler BEBIG, S.A
  • EDAP TMS
  • Elekta
  • F. Hoffman-La Roche AG
  • Ferring Pharmaceuticals
  • Galt Medical
  • GenomeDx Biosciences
  • Genomic Health
  • Gen-Probe
  • Genzyme
  • Gilead Science
  • Hologic
  • Hospira Inc.
  • Intuitive Surgical
  • Iris International
  • Johnson & Johnson (J&J)
  • Juniper Acquisition Corporation
  • Juniper Investment Company
  • MDx Health
  • Medivation
  • Metabolon
  • Metamark Genetics
  • Mitomics
  • Mylan Pharmaceuticals
  • Myriad Genetics
  • Needle Tech Products
  • Nucletron
  • OncoGenex
  • Oncura
  • Opko Health
  • Pfizer
  • Philips
  • Progenics Pharmaceuticals
  • Regeneron
  • Sandoz
  • Sanofi
  • Sanofi-Aventis
  • Siemens Healthcare
  • SonaCare Medical
  • Steba Biotech
  • Sython Pharmaceuticals
  • Takeda
  • Teva Pharmaceuticals
  • Theragenics
  • Tokai Pharmaceuticals
  • Tolmar Pharmaceuticals
  • Valeant Pharmaceuticals
  • Varian Medical Systems
  • Zydus Pharmaceuticals

Organisations Mentioned in the Report

  • American Cancer Society
  • Brazilian Pharmaceutical Price Regulation Board (CMED)
  • Cancer Research UK
  • Central Intelligence Agency (CIA)
  • European Partnership Action Against Cancer (EPAAC)
  • GLOBOCAN
  • Indian Brand Equity Foundation (IBEF)
  • International Agency for Research on Cancer (IRAC)
  • Japanese Ministry of Health, Labour, and Welfare (MHLW)
  • Memorial Sloan Kettering Cancer Center
  • Mount Siani Medical Centre (New York)
  • National Cancer Institute
  • National Institute of Clinical Excellence (NICE)
  • Oxford University
  • UK National Health Service (NHS)
  • University of California, Los Angeles (UCLA)
  • US Department of Defence
  • US Food and Drug Agency (FDA)
  • US Preventative Services Task Force (USPSTF)
  • Weizmann Institute
  • World Cancer Research Fund International
  • World Health Organization (WHO)
  • The Froedtert & Medical College of Wisconsin Clinical Cancer Centre
  • University Medical Centre Utrecht (Netherlands)
  • University of Texas MD Anderson Centre (Texas)
  • The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital (Netherlands)
  • Sunnybrook Health Sciences (Ontario)
Back to Top